SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 53.98-6.5%Nov 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (166)10/27/2006 10:10:52 AM
From: Arthur Radley   of 507
 
Reality finally setting in for NKTRs future...Morgan Stanley downgrades to Underweight today..

--Morgan Stanley said the downgrade was partly due to the slow launch of Exubera, a new form of inhaler insulin and lack of patient demand among other reasons.

--The brokerage believes the company's expense infrastructure is hugely levered to the success of Exubera and with peak consensus forecasts still in the $2.0 billion range, it views Nektar's profit outlook and shares as vulnerable.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News